StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Share price

<< Previous

Bullboard Posts

Next >>

Comment by 4real4everon Aug 08, 2022 2:35pm

196 Views

Post# 34879496

RE:RE:Share price

That means you think the share price can't be higher than $0,60 and $0,80

LithLover (824)

August 15, 2016 - 04:45 PM

89 Reads

Post# 25143634

Thanks. Love the low float. This could pop to $1 in no time flat.

Many years before the 8:1 consolidation Where's your $8 six years later

LithLover wrote: Operating costs last quarter were $2.6 million. Total operating costs of $9.2 million for full 2021.

If they were able to cut costs and/or bring in enough revenues to stay neutral. Say $2-2.2 million in revenues and cutting costs or $3 million in revenues with existing costs, either way that would be a very big step. With annual revenues at $10-12 million while remaining cash flow positive, that would value the company in the $60-80 million range.

If they had to do some creative financing or internal funding that we just haven't learned about yet, well that's a different story but it should still value the company higher than where it's sitting now at $11 million.

Q2 results are due Aug 15 by midnight which likely means after market closes on the Monday. I assume we will hear soon about a 2nd quarter conference call for Tuesday Aug 16 before market opens.